Hadassah

Hadassah Researchers Identify Source of Blood Clots in COVID-19 Patients

Tuesday, Jun 16 2020

Prof. Higazi and lab manager Suhair Abdee

Researchers around the world have been puzzled by a deadly COVID-19 complication that affects 30 percent of patients: the formation of large and small blood clots that create lethal blockages in the patient’s lungs, kidneys, heart, and brain. Prof. Abd Al-Roof Higazi, head of the Hadassah Medical Organization’s Department of Clinical Biochemistry and Division of Laboratories, has identified the mechanism that causes these clots.

Prof. Higazi and international colleagues published a seminal paper in the leading medical journal Blood about their discovery that alpha-defensin, a peptide (an amino-acid chain) speeds up the creation of blood clots and prevents their disintegration. This finding is crucial in understanding what is happening to COVID-19 patients because existing anticoagulant drugs don't impact alpha-defensin.

“We took blood samples from patients in Hadassah’s COVID-19 Outbreak department,” relates Prof. Higazi, “and found a high concentration of alpha-defensin.” The sicker the patient was, the researchers found, the higher the concentration of this peptide.

Prof. Higazi and lab manager Suhair Abdeen are working on a new way to dissolve the blood clots. They are testing colchicine, an oral medication used for gout and Familial Mediterranean fever. It has succeeded in reducing alpha-defensin levels and blood clots in mice, and they are awaiting approval to begin human trials.

Prof. Higazi believes if the drug reduces blood clots in COVID-19 patients, it will vastly reduce the numbers of patients needing respirators. “These patients have numerous blood clots in their lungs, preventing normative blood flow,” he explains.

In addition, he says, “We can give the drug to those with mild symptoms to prevent the development of blood clots.”

Read more.
Israel21C
The Jerusalem Post

Related Stories

alt_text

Wednesday, Dec 2 2020

Hadassah Opens Follow-Up Clinic for Recovered COVID-19 Patients

In response to the large number of COVID-19 patients suffering from lingering health issues long after they recover from the virus, Hadassah Hospital Ein Kerem has opened a multidisciplinary clinic at its Pulmonary Institute to monitor and assess their physical and psychological symptoms.

READ MORE ›
alt_text

Tuesday, Dec 1 2020

One in 200,000: Identical Triplets Born at Hadassah Hospital Mount Scopus

Last year, Tamar gave birth to a stillborn baby. When she became pregnant again, she initially didn’t rush to have an ultrasound because of the pandemic. But she wanted to make sure there was a heartbeat, and so she went to Hadassah Hospital Mount Scopus for that ultrasound. There were three heartbeats—belonging to three identical babies!

READ MORE ›
alt_text

Tuesday, Dec 1 2020

Hadassah Completes Phase I Trial With Israeli-Made COVID-19 Vaccine

Phase I of the first clinical trial with Brilife, the COVID-19 vaccine developed by the Israel Institute for Biological Research, was completed at Hadassah Hospital Ein Kerem on November 26, when the 40th participant received the final dose.

READ MORE ›
alt_text

Tuesday, Nov 24 2020

[Hadassah On Call Podcast] COVID's Long-Term Health Impact, an Insider's Perspective

It's no longer enough to find a COVID-19 cure. Each day, we're discovering long-term complications for those who have recovered from the virus.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

More ›

Show More